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 Oncogenic osteomalacia has recently been recognized to be a 
phosphate wasting state caused by the secretion from a tumor of fibroblast 
growth factor-23 (FGF-23), which inhibits the renal tubular epithelial 
phosphate transport [1]. The majority of the oncogenic 
osteomalacia-associated mesenchymal tumors are considered to belong to 
the category of phosphaturic mesenchymal tumors, mixed connective tissue 
(PMTMCT) variant [2].  
 PMTMCT typically follows a benign clinical course [2], and 
malignant cases are very rare [3].  
 We herein report a case of a recurrent malignant PMTMCT variant 
which arose in the tongue. This report was approved by The University 
Committee for Medical Research. 
 
Case report 
 In 2002, a 48-year-old male consulted our clinic due to symptoms 
of oral bleeding. The physical examination revealed gibbosity and a 3×5 
cm hard tumor in the middle of the tongue (Fig. 1). He had been receiving 
vitamin D, calcium, and phosphate for 2 years from a local community 
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hospital. The serum calcium and parathyroid hormone level showed a 
normal concentration when he visited our clinic. However, the serum 
phosphate level was markedly decreased (1.0 mg/dl, normal; 2.2-4.4 mg/dl). 
Radiographs revealed deformity of the thoracic and lumbar vertebrae, and 
thinning of the cortical bone.  
 The tumor was marginally resected, having been diagnosed to be a 
benign giant cell tumor by the biopsy prior to the operation. However, 
based on an examination of the surgical specimen, the tumor was diagnosed 
to be a malignant PMTMCT variant as focal areas of high nuclear grade, 
high cellularity, and elevated mitotic activity (Fig. 2). After the operation, 
the hypophosphatemia improved. The expression of the FGF-23 gene 
product was detected by a reverse transcriptase polymerase chain reaction 
(RT-PCR) analysis from the tumor (Fig. 3).  
 In 2003, the tumor recurred in the oral floor. An additional resection 
was thus performed with reconstruction using a scapular-latissimus dorsi 
osteocutaneous flap. In 2004, the tumor recurred at the oral cavity and the 
cervical lymph nodes. As surgery with sufficient margins was expected to 
result in severe morbidity, the patient was treated with radiotherapy (66 Gy). 
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The oral tumor and the lymph nodes thereafter markedly decreased. The 
tumors did not completely disappear; however, hypophosphatemia has not 
progressed for 2 years while the tumor slowly growing (Fig. 4).  
 
Discussion 
Since oncogenic osteomalacia was first described in 1959, it has 
been recognized that mesenchymal tumor-associated osteomalacia is 
resistant to high-dose vitamin D therapy and that a complete tumor 
resection results in a dramatic reversal of both hypophosphatemia and 
hyperphosphaturia [4]. In accordance with the tumor recurrence and 
resection, the hypophosphatemia in our case progressed and improved. 
These findings seen in our patient are therefore consistent with the typical 
course of oncogenic osteomalacia.  
The production of FGF-23 was considered to be a main 
pathophysiology of oncogenic osteomalacia [1, 5]. Interestingly, the serum 
phosphate level did not decrease after radiotherapy while the tumor has 
been very slowly regrowing after it initially decreased in size during 
radiotherapy. So far, we could find no report that regarded such a unique 
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phenomenon. 
Most cases of PMTMCT variant behave in a benign fashion [2]. 
Even in histologically malignant tumors, either local recurrence or distant 
metastasis is extremely rare [3]. In general, definitive radiotherapy is not 
considered as an effective treatment. However, this case tells us that 
PMTMCT is capable of acting in a rather malignant manner, and the 
FGF-23 producing property of the tumor might be changed by the 
radiotherapy. Radiotherapy may therefore be considered as an alternative 





[1] Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. 
Cloning and characterization of FGF-23 as causative factor of 
tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98:6500-6505. 
 
[2] Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho 
JY, et al. Most Osteomalacia-associated Mesenchymal Tumors Are a Single 
Histopathologic Entity. An Analysis of 32 Cases and a Comprehensive 
Review of the Literature. Am J Surg Pathol 2004;28:1-30. 
 
[3] Ogose A Hotta T, Emura I, Hatano H, Inoue Y, Umezu H, et al. 
Recurrent malignant variant of phosphaturic mesenchymal tumor with 
oncogenic osteomalacia. Skeletal Radiol 2001;30:99-103.  
 
[4] Schapira D, Ben-Izhak O, Nachtigal A, Burstein A, Shalom RB, 
Shagrawi I, et al. Tumor-induced osteomalacia. Semin Arthritis Rheum 
1995;25:35-46. 
 
[5] ADHR Consortium. Autosomal dominant hypophosphatemic rickets is 





Fig. 1: The tumor located at the center of the tongue.  
Fig.2: A histological analysis of the tumor (a; x100, b; x400). The tumor 
was diagnosed to be a malignant PMTMCT, based on the focal areas of a 
high nuclear grade, high cellularity, and elevated mitotic activity. 
Fig.3: A RT-PCR analysis for the FGF-23 transcript expression. A 303-bp 
band presenting FGF-23 was present in this tumor lane. 
Fig. 4: Treatment course and serum phosphate level.  
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